256 Newsroom — Uganda's Digital News Infrastructure
Health

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer - Nature

Published by Nature.com 11 August 2026 at 13:18
Share
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer - Nature
Image · Nature.com

What the report says

Circulating tumor DNA analyses in 44 patients with pancreatic cancer receiving the RAS(ON) multi-selective inhibitor daraxonrasib as part of a phase 1/2 trial, and preclinical translational modeling approaches, identify mechanisms of acquired resistance to mo…

Read the full report at Nature.com →

Loading debate for this article…

Other publishers covering this story

No additional verified coverage is currently clustered with this report.

More stories by this journalist

Other publications from this journalist — open any story without leaving the article page.

No other published stories from this publisher yet.

Related reporting

NMS Pledges to Address Medicine Shortages, Delivery Delays in WakisoNile Post 256 Newsroom Charcoal Grill serves up healthier dining - Daily MonitorDaily Monitor Development of a multiplex quantitative real-time PCR (qPCR) assay for simultaneous detection of Schistosoma haematobium and high-risk human papillomavirusesPlos.org How warnings can help persuade kids to curb their social media use - cnn.comCNN An early sign of dementia may be hiding in your voice, new research suggests - The Washington PostThe Washington Post Alcohol-linked cancer deaths have doubled in recent decades. What to know about risk. - The Washington PostThe Washington Post